Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have been given an average recommendation of “Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $51.75.
A number of analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research report on Monday. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd.
Read Our Latest Research Report on Vera Therapeutics
Vera Therapeutics Stock Performance
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). As a group, sell-side analysts anticipate that Vera Therapeutics will post -2.59 EPS for the current year.
Insider Transactions at Vera Therapeutics
In related news, CEO Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96. Following the transaction, the chief executive officer now owns 322,667 shares of the company’s stock, valued at $12,829,239.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 21.70% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC bought a new stake in Vera Therapeutics in the 1st quarter worth about $227,027,000. Kynam Capital Management LP boosted its stake in shares of Vera Therapeutics by 23.5% in the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock worth $56,142,000 after buying an additional 694,286 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Vera Therapeutics in the first quarter valued at approximately $103,189,000. Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics by 31.5% in the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after acquiring an additional 515,106 shares in the last quarter. Finally, Samlyn Capital LLC increased its position in shares of Vera Therapeutics by 90.8% during the second quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after acquiring an additional 586,410 shares during the last quarter. 99.21% of the stock is owned by institutional investors.
Vera Therapeutics Company Profile
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading
- Five stocks we like better than Vera Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is the S&P 500 and How It is Distinct from Other Indexes
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Want to Profit on the Downtrend? Downtrends, Explained.
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.